I85PREP
⌘ K
PPB PharmTech study materials
PPB PharmTech study resources

PPB PharmTech practice questions

One question at a time. Build your PPB PharmTech understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Registration and Marketing Authorisation (MA)

Under the EU pharmaceutical framework, which body is competent to grant a centralised marketing authorisation valid across all member states?

  1. The European Directorate for the Quality of Medicines
  2. The Heads of Medicines Agencies coordination group
  3. The European Commission acting on a CHMP opinion Correct answer.
  4. The national competent authority of the rapporteur member state

Explanation

The centralised procedure runs through the European Medicines Agency, where the Committee for Medicinal Products for Human Use issues an opinion, and the European Commission adopts the final decision that applies in every member state. National authorities play no granting role in that route.

Question 2Registration and Marketing Authorisation (MA)

A company wants to market a new chemical entity in several EU member states and chooses the decentralised procedure. What must exist before the application is submitted?

  1. A mutual recognition decision from a previous national approval
  2. A completed centralised assessment report from the EMA
  3. A reference member state agreed among the concerned member states Correct answer.
  4. A WHO prequalification certificate for the product

Explanation

In the decentralised procedure the applicant selects a reference member state whose assessment is relied on by the concerned member states, and that RMS must be identified at submission. There is no prior approval and no centralised assessment in this route.

Question 3Registration and Marketing Authorisation (MA)

Which document in a marketing authorisation dossier provides the critical expert assessment of the benefit-risk balance and is required in the EU format?

  1. The certificate of suitability for a pharmacopoeial substance
  2. The investigator's brochure of Module 1
  3. The clinical overview of Module 2 Correct answer.
  4. The pharmacovigilance system master file

Explanation

Module 2 of the Common Technical Document contains the quality, non-clinical and clinical summaries, and the clinical overview is the critical expert analysis of benefit-risk. The other documents serve different regulatory purposes.

Question 4Registration and Marketing Authorisation (MA)

An applicant submits a marketing authorisation application for a generic product. Which abridged legal basis applies in the EU?

  1. Article 10a of Directive 2001/83/EC
  2. Article 10b of Directive 2001/83/EC
  3. Article 8(3) of Directive 2001/83/EC
  4. Article 10(1) of Directive 2001/83/EC Correct answer.

Explanation

Article 10(1) is the generic abridged route, allowing reliance on the reference product's dossier instead of full non-clinical and clinical data. Article 8(3) is the full dossier, while 10a and 10b cover well-established use and fixed combinations respectively.

Question 5Registration and Marketing Authorisation (MA)

Before a generic application can be accepted in the EU, what must be true of the reference medicinal product?

  1. It has been withdrawn from the market for at least one year
  2. It is listed in the WHO essential medicines list
  3. It has been authorised for at least eight years in a member state Correct answer.
  4. It is authorised only through the centralised procedure

Explanation

The generic route relies on an eight-year data exclusivity period from the reference product's first EU authorisation, after which the application may be submitted. Marketing of the generic can generally start only after a further two years of protection.

Question 6Registration and Marketing Authorisation (MA)

A medicine is authorised in one member state and the holder now wants the same authorisation recognised in three other member states. Which procedure is designed for this situation?

  1. The decentralised procedure
  2. The mutual recognition procedure Correct answer.
  3. The national procedure
  4. The centralised procedure

Explanation

The mutual recognition procedure starts from an existing national authorisation and extends it to concerned member states that recognise the reference assessment. The decentralised procedure applies when no national authorisation exists yet.

Question 7Registration and Marketing Authorisation (MA)

Which outcome is possible at the end of a referral under Article 31 of Directive 2001/83/EC concerning a product already on the market?

  1. Immediate suspension of the product for ten years
  2. Conversion of every national authorisation into a centralised one
  3. A harmonised EU decision on the conditions of authorisation Correct answer.
  4. Automatic revocation of all marketing authorisations without review

Explanation

An Article 31 referral allows the CHMP to review a safety or quality concern and issue an opinion that results in harmonised conditions, variations or, where justified, suspension or withdrawal. The decision is proportionate and evidence-based rather than automatic.

Question 8Registration and Marketing Authorisation (MA)

A company plans a paediatric investigation plan for a new medicinal product. To which body must the plan be submitted for agreement?

  1. The European Pharmacopoeia Commission
  2. The national ethics committee of the reference member state
  3. The Paediatric Committee of the European Medicines Agency Correct answer.
  4. The European Commission's pharmaceutical unit

Explanation

The Paediatric Committee (PDCO) assesses and agrees paediatric investigation plans, and compliance with the agreed plan is checked at the time of the marketing authorisation application. The other bodies have no role in agreeing PIPs.

Question 9Registration and Marketing Authorisation (MA)

Which incentive does the EU orphan designation provide to a sponsor of a qualifying medicinal product?

  1. Permanent exemption from all pharmacovigilance obligations
  2. Ten years of market exclusivity from the date of authorisation Correct answer.
  3. Automatic centralised authorisation without any assessment
  4. A guaranteed public procurement contract in every member state

Explanation

Orphan designation grants ten years of market exclusivity once the product is authorised, subject to defined exceptions such as a similar product showing clinical superiority. It does not remove assessment or safety obligations.

Question 10Registration and Marketing Authorisation (MA)

A marketing authorisation holder wants to add a new therapeutic indication to an existing EU authorisation. Which regulatory action is required?

  1. A variation application to the competent authority Correct answer.
  2. A clinical trial authorisation
  3. A notification to the European Pharmacopoeia
  4. A new full marketing authorisation application

Explanation

Adding an indication changes the terms of the existing authorisation and must be filed as a variation, classified under the variations regulation. A new authorisation is not needed because the product and holder remain the same.

Question 11Registration and Marketing Authorisation (MA)

Under the EU variations classification, which type of change requires assessment by the competent authority before it can be implemented?

  1. A change in the name of the local distributor
  2. A minor editorial correction to the package leaflet
  3. An extension of indication Correct answer.
  4. A change of the marketing authorisation holder's contact details

Explanation

Extensions of indication are substantial changes that affect the benefit-risk profile and require prior approval through a variation. Administrative updates such as contact details or distributor names follow lighter notification routes.

Question 12Registration and Marketing Authorisation (MA)

What is the main purpose of the renewal procedure for a marketing authorisation in the EU?

  1. To transfer the authorisation to a different legal entity
  2. To reassess the benefit-risk balance after an initial five-year period Correct answer.
  3. To extend data exclusivity by a further five years
  4. To convert the authorisation into a centralised one

Explanation

The first authorisation is valid for five years and must be renewed once, when the authority re-evaluates the benefit-risk balance. After that first renewal, authorisations are generally valid indefinitely unless safety grounds require otherwise.

Question 13Registration and Marketing Authorisation (MA)

Which element must a marketing authorisation application include to demonstrate that the manufacturing site operates in compliance with good manufacturing practice?

  1. A marketing survey of prescriber preferences
  2. A letter of support from a patient organisation
  3. Evidence of a valid GMP certificate or equivalent inspection outcome Correct answer.
  4. A copy of the company's annual financial report

Explanation

The dossier must show that manufacturing and importation sites hold valid GMP documentation or have been inspected acceptably. Prescriber surveys, financial reports and patient letters are not regulatory evidence of GMP compliance.

Question 14Registration and Marketing Authorisation (MA)

A sponsor wishes to rely on published scientific literature to support a well-established medicinal use claim. What must be demonstrated for the active substance?

  1. Exclusive supply by a single manufacturer for a decade
  2. Approval in at least five non-EU countries within the last year
  3. Systematic and documented use for at least ten years in the EU with recognised efficacy and acceptable safety Correct answer.
  4. Use for at least two years in any country with no reported adverse events

Explanation

The well-established use route under Article 10a requires ten years of systematic and documented medicinal use within the EU, together with recognised efficacy and an acceptable safety profile. Short-term or non-EU use alone does not satisfy the requirement.

Question 15Registration and Marketing Authorisation (MA)

Which document does the marketing authorisation holder use to communicate agreed product information changes to prescribers and patients after approval?

  1. An updated summary of product characteristics and package leaflet Correct answer.
  2. The certificate of analysis
  3. The development safety update report
  4. The investigator's brochure

Explanation

The summary of product characteristics and package leaflet are the approved product information, and they are updated through variations whenever terms change. The other documents relate to trials or batch quality.

Question 16Registration and Marketing Authorisation (MA)

A company wants a single EU authorisation for a product containing a new active substance for which no other application is pending. Which route is most appropriate?

  1. The mutual recognition procedure, because it saves assessment time
  2. The decentralised procedure, because it avoids the EMA
  3. The national procedure, because it limits the scope to one market
  4. The centralised procedure, because the product contains a new active substance Correct answer.

Explanation

Products containing a new active substance not previously authorised in the EU fall within the mandatory scope of the centralised procedure. The other routes either require an existing national authorisation or limit the territorial scope.

Question 17Registration and Marketing Authorisation (MA)

Which requirement applies to the naming of a medicinal product in an EU marketing authorisation application?

  1. The invented name must be identical to the international non-proprietary name
  2. The invented name must include the applicant's company name
  3. The invented name must be approved by the European Pharmacopoeia
  4. The invented name must not be misleading and must not conflict with an existing name Correct answer.

Explanation

Invented names are assessed for misleading claims and for potential confusion with existing medicinal product names. They are distinct from the international non-proprietary name and need not contain the company name.

Question 18Registration and Marketing Authorisation (MA)

During assessment of an application, a member state raises a serious objection in the decentralised procedure. What is the consequence if the concerned member states cannot reach agreement?

  1. The matter is referred to the CHMP for arbitration Correct answer.
  2. The applicant must withdraw and resubmit nationally
  3. The product is authorised with the objection recorded as a condition
  4. The application is automatically approved by the reference member state

Explanation

Unresolved disagreements in the decentralised and mutual recognition procedures are escalated to the CHMP for binding arbitration. Neither automatic approval nor authorisation with unresolved objections is a valid outcome.

Question 19Registration and Marketing Authorisation (MA)

An applicant submits a generic application before the reference product's data exclusivity period has expired but after the eight-year point. What is the regulatory position?

  1. The application may be submitted and the product marketed immediately
  2. The application may be submitted and assessed, but the product may not be marketed until the ten-year point Correct answer.
  3. The application must wait until the ten-year point before submission
  4. The application must be rejected as inadmissible

Explanation

The EU framework separates submission from market entry: a generic application can be filed after eight years of the reference product's protection, while marketing can begin only after the full ten-year period. This allows assessment to run in parallel with the remaining exclusivity.

Question 20Registration and Marketing Authorisation (MA)

A marketing authorisation holder plans to change the manufacturer of the active substance. How should this be handled?

  1. Through a variation, with data on the new manufacturer and comparability Correct answer.
  2. Through a notification to the European Pharmacopoeia
  3. Through the renewal procedure at the five-year point
  4. Through a new marketing authorisation application

Explanation

Changing the active substance manufacturer is a quality change to the authorised dossier and must be filed as a variation, supported by information on the new site and evidence of comparability. It is not a new product and is unrelated to renewal.

Question 21Registration and Marketing Authorisation (MA)

Which statement best describes the role of the European public assessment report (EPAR)?

  1. It replaces the summary of product characteristics for nationally authorised products
  2. It publishes the scientific assessment and product information for centrally authorised medicines Correct answer.
  3. It certifies that each batch meets specification
  4. It is a confidential document available only to the applicant

Explanation

The EPAR is published by the EMA after a centralised authorisation and summarises the scientific assessment together with the approved product information. It is public and does not replace national product information or certify batches.

Question 22Registration and Marketing Authorisation (MA)

A product authorised nationally is suspected of causing a serious safety issue across the EU. Which mechanism allows a harmonised EU review of the matter?

  1. A certificate of suitability renewal
  2. A referral under Article 31 of Directive 2001/83/EC Correct answer.
  3. A renewal application by the holder
  4. A paediatric investigation plan modification

Explanation

An Article 31 referral enables the CHMP to assess a safety, quality or efficacy concern for nationally authorised products and issue an EU-wide harmonised outcome. Renewals, PIPs and CEPs address different regulatory needs.

Question 23Registration and Marketing Authorisation (MA)

Which consideration applies when a company seeks a conditional marketing authorisation in the EU?

  1. The product must be a generic of an existing reference medicine
  2. The product must already be authorised in at least three member states
  3. The benefit-risk balance must be positive and the product must address an unmet medical need Correct answer.
  4. The applicant must waive all post-authorisation obligations

Explanation

Conditional authorisations are available for products with a positive benefit-risk balance that address an unmet medical need, with comprehensive data to be provided later through specific obligations. They are not available for generics and do not waive post-authorisation duties.

Question 24Registration and Marketing Authorisation (MA)

What is the function of the letter of access in an EU marketing authorisation application?

  1. It authorises the product to be exported outside the EU
  2. It replaces the need for a GMP inspection
  3. It confirms that the applicant owns the manufacturing site
  4. It allows the applicant to rely on data held by another party Correct answer.

Explanation

A letter of access is provided by a data owner so that the applicant may reference that party's proprietary data, for example a certificate of suitability or a master file. It does not confer site ownership or replace inspections.

Question 25Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Under the Pharmacy Board's licensing framework, which document authorizes a registered pharmacist to lawfully compound and dispense prescriptions at a specific premises?

  1. A wholesale dealer's licence held by the owner
  2. A continuing professional development portfolio receipt
  3. A personal professional indemnity insurance certificate
  4. A premises licence issued for that pharmacy location Correct answer.

Explanation

A premises licence is tied to a specific physical location and permits the licensed activities of compounding and dispensing to occur there. Personal documents such as insurance or CPD records support the pharmacist but do not authorize the premises to operate. A wholesale dealer's licence covers distribution, not patient dispensing.

Question 26Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacist's registration is described as 'annual' in the licensing system. What does this most directly require the registrant to do each year?

  1. Retake the full registration examination
  2. Change their registered pharmacy employer
  3. Reapply for a new premises licence
  4. Submit a renewal application with the required fee and declaration of fitness to practise Correct answer.

Explanation

Annual registration renewal requires a renewal application, the prescribed fee, and a declaration that the registrant remains fit to practise. It does not require re-examination or a change of employer. Premises licensing is a separate process from personal registration.

Question 27Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Which statement best describes the purpose of Good Pharmacy Practice (GPP) standards in day-to-day pharmacy operations?

  1. They replace the need for a premises licence
  2. They set the retail price of prescription medicines
  3. They specify the tax treatment of pharmacy sales
  4. They define minimum quality expectations for pharmacy services and patient care Correct answer.

Explanation

GPP standards describe the minimum quality expectations for pharmacy services, including patient care, premises, and staff competence. They are quality benchmarks rather than commercial or fiscal rules. They complement, but do not replace, licensing requirements.

Question 28Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacy technician asks why the pharmacy keeps a written standard operating procedure (SOP) for dispensing. Which response aligns with GPP expectations?

  1. SOPs ensure tasks are performed consistently and to an agreed quality standard Correct answer.
  2. SOPs exist to satisfy insurers rather than to guide practice
  3. SOPs are only needed when the pharmacy employs more than ten staff
  4. SOPs are optional documents kept for inspection decoration

Explanation

SOPs are a core GPP tool that standardizes how tasks are carried out so that quality and safety are consistent regardless of who performs the task. They apply to all pharmacies regardless of staff numbers. Their purpose is operational guidance, not merely satisfying insurers or inspectors.

Question 29Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Which activity counts as continuing professional development (CPD) for a registered pharmacist?

  1. Recording a reflective learning entry after attending a clinical webinar Correct answer.
  2. Reading a novel during annual leave
  3. Renewing the premises licence on time
  4. Working overtime without any reflection or record

Explanation

CPD is a structured, recorded process in which learning is documented and reflected upon, such as a reflective entry after a clinical webinar. Simply working overtime or reading for leisure does not constitute recorded CPD. Premises licence renewal is an administrative licensing task, not professional learning.

Question 30Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacy is relocating to a new address within the same city. What licensing action is required before dispensing from the new site?

  1. Ask staff to sign a new employment contract
  2. Only update the pharmacy's website address
  3. Continue dispensing and notify the board after six months
  4. Apply to vary or obtain a premises licence for the new address Correct answer.

Explanation

Because a premises licence is tied to a specific location, moving to a new address requires a variation or new premises licence before dispensing there. Operating first and notifying later is non-compliant. Website updates and employment contracts do not address the licensing requirement.

Question 31Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Which element is typically required in a pharmacist's CPD record to demonstrate meaningful learning?

  1. The exact duration of the pharmacist's lunch break
  2. A list of colleagues who attended the same event
  3. A reflection linking the learning to the pharmacist's own practice Correct answer.
  4. A copy of the venue's fire safety certificate

Explanation

A meaningful CPD record includes reflection on what was learned and how it will change or inform the pharmacist's practice. Attendance lists, venue certificates, and break times do not demonstrate learning. The reflective component is what distinguishes CPD from simple event attendance.

Question 32Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A patient asks for a medicine that requires a prescription, but the pharmacy's licence only covers retail sale of over-the-counter products. What is the most appropriate action?

  1. Borrow stock from a licensed pharmacy and dispense without documentation
  2. Dispense the medicine and record it as an over-the-counter sale
  3. Dispense the medicine because the patient requested it
  4. Explain that the pharmacy is not licensed to supply that medicine and refer the patient appropriately Correct answer.

Explanation

Supplying prescription medicines requires the appropriate licence and authorization; a pharmacy limited to over-the-counter retail cannot dispense them. The correct response is to explain the limitation and refer the patient to a suitably licensed provider. Dispensing without authorization, or misrecording a prescription medicine as an OTC sale, is non-compliant.

Question 33Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacist has completed 40 hours of CPD activities but has recorded no reflection on any of them. How would a regulator most likely view this portfolio?

  1. As superior, because reflection is optional
  2. As incomplete, because reflection is required to demonstrate the learning's impact on practice Correct answer.
  3. As fully compliant, because the hours exceed the minimum
  4. As irrelevant, because hours are the only criterion

Explanation

CPD frameworks generally require both participation and reflection; hours alone do not show that learning has been integrated into practice. A portfolio with activities but no reflection is typically regarded as incomplete. Exceeding the minimum hours does not compensate for the missing reflective component.

Question 34Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Which situation best illustrates a breach of Good Pharmacy Practice relating to premises and equipment?

  1. A refrigerator storing vaccines has no temperature monitoring record Correct answer.
  2. A pharmacist attends a clinical update webinar
  3. A technician follows a written dispensing SOP
  4. A pharmacy displays its opening hours on the door

Explanation

GPP requires that equipment critical to product quality, such as vaccine refrigerators, be monitored and documented to ensure the cold chain is maintained. The absence of temperature records is a quality breach. Attending training, displaying hours, and following SOPs are all compliant practices.

Question 35Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A newly qualified pharmacist wants to expand into providing a vaccination service. What is the most appropriate first step under licensing and training frameworks?

  1. Delegate all vaccinations to untrained counter staff
  2. Confirm the service is permitted under the licence and complete accredited training before delivering it Correct answer.
  3. Advertise the service before confirming any authorization
  4. Begin vaccinating immediately and complete training within the year

Explanation

New services must be within the scope of the pharmacy's authorization, and the pharmacist must hold the required accredited training and competence before delivery. Starting first and training later exposes patients to risk and breaches requirements. Delegating clinical tasks to untrained staff or advertising unapproved services is non-compliant.

Question 36Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Which approach best demonstrates that a pharmacy's training program supports GPP competence requirements?

  1. Training needs are identified, delivered, and documented for each staff role Correct answer.
  2. Training records are discarded after one month
  3. Staff are assumed competent once hired
  4. Training is delivered only when an inspector visits

Explanation

A GPP-aligned training program identifies role-specific needs, delivers appropriate training, and keeps documentation showing competence. Reactive training only at inspection time or assuming competence at hire fails to demonstrate ongoing competence. Discarding records removes the evidence needed for review.

Question 37Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacist moves from community practice to a hospital dispensary. How should their CPD plan change?

  1. It should remain identical because CPD is generic
  2. It should stop until the probation period ends
  3. It should be re-focused on the competencies and risks of the new hospital role Correct answer.
  4. It should focus only on administrative tasks

Explanation

CPD should be relevant to the pharmacist's current scope of practice, so a change of setting requires re-focusing learning on the new role's competencies and risks. Keeping an identical plan ignores the different demands of hospital practice. Suspending CPD or focusing only on administration would leave clinical competence gaps.

Question 38Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Which record would best provide evidence that a pharmacy's staff have maintained competence in aseptic technique?

  1. Dated competency assessments with observed technique and feedback Correct answer.
  2. A staff roster showing who worked each shift
  3. A supplier invoice for consumables
  4. A customer satisfaction survey

Explanation

Competence in a practical skill such as aseptic technique is evidenced by documented, dated assessments that include observation and feedback. Rosters show attendance, not competence. Invoices and satisfaction surveys do not demonstrate technical skill.

Question 39Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacy owner proposes to let the premises licence lapse for two weeks while refurbishing, continuing to sell medicines throughout. What is the key compliance concern?

  1. The lapse is acceptable if customers are informed
  2. Selling medicines without a valid premises licence during the lapse is unlawful Correct answer.
  3. Refurbishment always requires a new owner
  4. Selling medicines is permitted if the pharmacist is registered

Explanation

Licensed activities require a valid premises licence at all times; allowing it to lapse while continuing to sell medicines is unlawful. A registered pharmacist's presence does not substitute for a valid premises licence. Informing customers does not cure the licensing gap.

Question 40Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

Which statement correctly distinguishes registration from licensing in pharmacy regulation?

  1. Registration applies to individuals; premises licensing applies to facilities Correct answer.
  2. Registration is voluntary; licensing is mandatory
  3. Both terms describe the same certificate
  4. Registration applies to facilities; licensing applies to individuals

Explanation

Registration generally concerns individual practitioners, confirming they are fit and qualified to practise, while premises licensing authorizes a facility to carry out specified activities. The two are distinct processes with different subjects. They are not interchangeable, and registration is not voluntary.

Question 41Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacy wants to introduce an online repeat-prescription ordering system. Which GPP consideration is most relevant before launch?

  1. Ensuring identity verification, confidentiality, and clear escalation pathways are built in Correct answer.
  2. Removing pharmacist review to speed up processing
  3. Maximizing the number of orders per hour regardless of safety
  4. Allowing any staff member to approve prescriptions

Explanation

Digital services must preserve patient safety and confidentiality, including verifying identity and providing clear routes for escalation and pharmacist review. Prioritizing throughput over safety or removing pharmacist review undermines GPP. Allowing untrained staff to approve prescriptions breaches competence and authorization rules.

Question 42Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacist identifies a recurring dispensing error and wants to use it as a learning opportunity. Which CPD-aligned action is most appropriate?

  1. Record a reflective entry analyzing the cause and the change made to prevent recurrence Correct answer.
  2. Blame the individual and take no further action
  3. Ignore the error because CPD only covers formal courses
  4. Delete the incident record to protect the pharmacy

Explanation

Reflective learning from significant events, including errors, is a recognized CPD method that links analysis to practice improvement. CPD is not limited to formal courses. Blaming individuals without system review or deleting records undermines learning and governance.

Question 43Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A regulator's inspection finds that a pharmacy's SOPs were written three years ago and have never been reviewed despite changes in suppliers and equipment. What is the most accurate assessment?

  1. The SOPs are likely non-compliant because they no longer reflect current practice Correct answer.
  2. The SOPs are irrelevant to GPP inspections
  3. The SOPs are compliant because they exist in written form
  4. The SOPs are compliant if staff can recite them from memory

Explanation

SOPs must be reviewed and updated when processes, suppliers, or equipment change so that they accurately reflect current practice. Mere existence of a document does not satisfy GPP. Staff memory does not compensate for outdated written procedures, and SOPs are a routine inspection focus.

Question 44Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacist completes an online course but the content is unrelated to their role and they cannot describe any practice change. How should this be judged against CPD quality criteria?

  1. It is mandatory to record regardless of relevance
  2. It has limited value because relevant learning and demonstrable practice impact are expected Correct answer.
  3. It is fully compliant because a certificate was issued
  4. It is excellent because any learning counts equally

Explanation

CPD quality depends on relevance to the practitioner's role and evidence of impact on practice, not merely on completing a course or obtaining a certificate. Learning unrelated to the role with no demonstrable change has limited CPD value. Recording it is not prohibited, but its quality is low.

Question 45Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacy group operates several branches and rotates pharmacists between them. Which statement about premises licensing is correct?

  1. Each branch requires its own premises licence for the activities it performs Correct answer.
  2. Rotating pharmacists removes the need for branch licences
  3. One licence covers all branches under the group's name
  4. A licence is needed only for the largest branch

Explanation

Premises licences attach to individual locations, so every branch carrying out licensed activities needs its own licence. A group name does not extend a licence across sites. Branch size and staff rotation do not affect the requirement.

Question 46Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

During a CPD audit, a pharmacist submits a portfolio of certificates with no dates, no reflection, and no link to their scope of practice. What is the most likely outcome?

  1. The portfolio is rejected as insufficient evidence of meaningful CPD Correct answer.
  2. The portfolio is accepted because certificates are official
  3. The portfolio is forwarded to the premises licensing team
  4. The portfolio is accepted if the total hours are high

Explanation

Audit standards require dated, reflective records tied to the practitioner's scope of practice; undated certificates alone are insufficient evidence. Official certificates do not compensate for missing reflection and dates. High hours totals do not remedy the structural deficiencies, and premises licensing is a separate matter.

Question 47Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacy plans to add a compounding service for sterile products. Which combination of requirements is most critical before starting?

  1. A new logo and revised opening hours
  2. Appropriate premises and equipment validation plus trained, assessed competent staff Correct answer.
  3. Verbal assurance from the owner that standards are met
  4. A larger shop front and additional marketing

Explanation

Sterile compounding demands validated facilities, equipment, and environmental controls together with staff who are trained and assessed as competent. Marketing, branding, or opening-hour changes do not address the technical requirements. Verbal assurance without documented validation and competence is insufficient.

Question 48Licensing, Good Pharmacy Practice, Training and Continuing Professional Development (CPD)

A pharmacist is asked to supervise a trainee while also managing a busy dispensary. Which action best reflects GPP expectations for training and supervision?

  1. Allow the trainee to work unsupervised to save time
  2. Ensure supervision arrangements allow adequate oversight and documented competence sign-off Correct answer.
  3. Sign off competence without observing the trainee
  4. Delegate supervision to an untrained assistant

Explanation

GPP requires that trainees receive adequate supervision and that competence is confirmed through documented observation and sign-off. Leaving a trainee unsupervised or signing off without observation risks patient safety and undermines training integrity. Supervision cannot be delegated to untrained staff.

Question 49Regulatory Inspections

During a pre-approval inspection of a sterile fill-finish facility, the investigator observes that media fill vials are incubated for only 7 days before being discarded. Which action should the QA lead take first?

  1. Wait for the Form 483 to be issued before evaluating the practice
  2. Document the observation and continue, since 7 days exceeds the firm's internal minimum
  3. Discard the affected vials and restart the media fill without further review
  4. Evaluate the deviation against the validated incubation period and initiate a deviation investigation Correct answer.

Explanation

Any observed practice that departs from validated parameters must be evaluated against the validation documentation and handled through the deviation system, because the investigator will expect a documented assessment and CAPA. Reacting only after a Form 483 is issued leaves the observation unanswered during the inspection. Simply documenting without investigation does not demonstrate control of the process.

Question 50Regulatory Inspections

What is the primary purpose of an FDA Form 483 issued at the close of an inspection?

  1. To certify that the facility is compliant with current good manufacturing practice
  2. To suspend the facility's manufacturing operations immediately
  3. To impose monetary penalties for each observed deficiency
  4. To list inspectional observations that the firm may respond to in writing Correct answer.

Explanation

Form 483 records observations made by the investigator and gives the firm an opportunity to respond in writing with corrective actions. It is not itself an enforcement action and does not suspend operations or impose penalties. Compliance status is determined through later review, not by the form's issuance.